REGULATORY

MHLW Panel to Review Gilead’s Biktarvy, GSK’s Trelegy and More on Feb. 22

February 12, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Gilead Sciences’ HIV triplet known as Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide fumarate (TAF)) overseas and a throng of other drugs will come up for discussion by a key health ministry panel on February 22. If the thumbs-up is…

To read the full story

Kymriah Pre-Treatment Regimens Up for Review on Feb. 22
February 12, 2019

REGULATORY

Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…